Recognizing need for greater genomic
research productivity, NIH and Maryland Venture Fund put support
BETHESDA, MD - Apr 22, 2014 - BioDatomics™, a supplier of
bioinformatics analysis software and services that improve genomic
research productivity, has received a grant from the National
Institutes of Health (NIH) and a capital investment from the
Maryland Department of Business and Economic Development's (MDBED)
Maryland Venture Fund (MVF). These strategic investments will allow
the company to further expand the capabilities of their next
generation sequencing (NGS) data analysis platform, BioDT™.
The NIH continues to support NGS projects that focus on solving
Big Data challenges associated with genomic research, and on
democratizing access to advanced analysis platforms. With this NIH
grant, "Building an open-source cloud-based computational platform
to improve data access," BioDatomics will further expand its open
-source toolset, bringing these added capabilities to researchers
and bioinformaticians alike.
"BioDatomics and the NIH share a mutual goal of accelerating
genomic-based discoveries," said Alan Taffel, President of
BioDatomics. "While NGS funding has traditionally focused on
generating new data, there is now an obvious need for NGS users to
be able to glean insights from that data more quickly and
In addition to the NIH grant, BioDatomics also received an
investment from the MVF, which provides capital to innovative
Maryland-based technology companies. Recognizing the avalanche of
NGS data being generated by academic and commercial research
organizations, and the need to analyze that data more efficiently,
MVF took the opportunity to invest in a platform created
specifically for that purpose.
"BioDatomics operates at the intersection of two of Maryland's
fastest-growing sectors - biotechnology and big data. We are proud
to make this investment in BioDatomics and look forward to their
growth and success in Maryland," DBED Secretary Dominick Murray
said. "Supporting entrepreneurs and small businesses in high-tech,
high-growth fields is critical to the success of our economy and
State. Companies like BioDatomics are facilitating the development
of cutting-edge medicines, vaccines and technologies that keep us
safer, healthier and better-connected than ever before."
"The investment from the Maryland Venture Fund serves as a
validation of our approach and provides significant strategic value
well beyond a financial commitment," Taffel said.
Although several companies have recently entered the NGS data
analysis market, BioDatomics is the only one to have developed an
open-source solution built on the popular and powerful Hadoop® Big
Data analysis engine, which allows pipelines to execute up to 100
times faster than traditional platforms. BioDT also enhances
productivity by integrating many popular genomic analysis tools
into a single platform that provides drag-and-drop editing,
real-time collaboration, visualized results, and intuitive table
manipulation. The platform is available as a software license and
will shortly be released as a cloud-based service as well.
For more information, stop by the BioDatomics booth during the
Bio-IT World Conference & Expo taking place April 29th - May
1st in Boston or visit, www.biodatomics.com.
Research supported by theNational Institute on
Drug Abuse (NIDA)of the National Institutes of Health
under award number R43 DA036970.
The Maryland Department of Business and Economic Development
stimulates private investment and creates jobs by attracting new
businesses, encouraging the expansion and retention of existing
companies, and providing workforce training and financial
assistance to Maryland companies. The Department promotes the
State's many economic advantages and markets local products and
services at home and abroad to spur economic development and
international investment, trade and tourism. Because they are major
economic generators, the Department also supports the Arts, film
production, sports and other special events. For more information,
About BioDatomics, LLC
BioDatomics provides powerful yet intuitive bioinformatics
analysis software and services that improve genomic and biomedical
research productivity. The company's BioDT™ platform, which was
built by some of the world's most experienced computational and
molecular biologists, allows researchers and bioinformaticians to
more quickly glean insights from their data thanks to an
easier-to-use intuitive interface, dramatically reduced analysis
turnaround times and real-time collaboration between colleagues.
The result is accelerated development of new medical treatments and
other breakthroughs. BioDatomics was co-founded by Maxim Mikheev,
MD, PhD and local executives Anthony Millin, and Alan Taffel and is
headquartered in Bethesda, MD. Learn more at www.biodatomics.com.
Chempetitive Group for BioDatomics